| Literature DB >> 32607085 |
Heather Koehler1, Keely Puchalski2, Guillermo Ruiz2, Bertram Jacobs3, Jeffrey Langland2,3.
Abstract
Astragalus membranaceus is a staple of Traditional Chinese Medicine being one of the oldest medicinal herbs listed in the material medica of Chinese herbal medicine. Chinese herbalists have used Astragalus to help the human body fight a variety of diseases. Modern herbalists utilize Astragalus primarily as an immunostimulant to prevent common infection and aid in the recovery following infection. Historically, the biological activities associated with Astragalus have been accounted for, at least in part, to several constituents present in the botanical including saponins and polysaccharides. We propose that in addition to these constituents, compounds from endophytic (or epiphytic) bacteria present in (or on) the roots of Astragalus may have an important biological role. Lipopolysaccharides and lipoproteins are major components of Gram-negative bacteria and highly potent activators of the innate immune response. Our data supports a direct correlation between the level of immune gene induction and the level of lipopolysaccharides/lipoproteins present in the Astragalus extract. We demonstrate that extracts from Astragalus specifically activate Toll-like and NOD-like receptors involved in the recognition and response to bacterial constituents and that removal of the lipopolysaccharide/lipoprotein from the Astragalus extract reduced the level of this response. The results support that many immune enhancing botanicals have established a symbiotic relationship with Gram-negative bacteria and that the immune enhancing effect of these botanical extracts on the body may not only be due to endogenous plant compounds, but endophytic (or epiphytic) bacterial components as well.Entities:
Keywords: Astragalus membranceus; Rhizobium; botanical; endophytic bacteria; immune; lipopolysaccharide; lipoprotein
Mesh:
Substances:
Year: 2020 PMID: 32607085 PMCID: PMC7309664
Source DB: PubMed Journal: Yale J Biol Med ISSN: 0044-0086
Figure 1TLR/NOD receptor activation by . HEK293 cells stably expressing the indicated human TLR/NOD gene were treated with AM extracts at 10, 30, and 90 μg/ml. Control samples (C) were treated with manufacturer’s recommended receptor agonist. NF-κB activation was evaluated by expression of the NF-κB inducible reporter gene and secretion of SEAP. Error bars indicate the standard deviation from three separate trials.
Figure 2Inhibition of TLR/NOD activation by . HEK293 cells stably expressing the indicated human TLR/NOD gene were treated with AM extracts or AM extracts following LPS (endotoxin)/lipoprotein removal at 10, 30, and 90 μg/ml. NF-κB activation was evaluated by expression of the NF-κB inducible reporter gene and secretion of SEAP. Error bars indicate the standard deviation from three separate trials.
Figure 3Inhibition of TLR activation by . HEK293 cells stably expressing the indicated human TLR/NOD gene were treated with AM extracts or AM extracts treated with endotoxin neutralizing peptide at 10 and 30 μg/ml. NF-κB activation was evaluated by expression of the NF-κB inducible reporter gene and secretion of SEAP. Error bars indicate the standard deviation from three separate trials.
Figure 4Activation of human PBMC cells by . PBMCs were treated with vehicle (25% ethanol), AM extract, or AM extract following endotoxin removal at a dose of 10 μg/ml. At the time of harvest, cells were fixed, permeabilized, and probed with anti-human IFNγ Part A) or anti-human TNFα Part B). Stained cells were acquired on a BD LSR II Fortessa flow cytometer and analyzed using FlowJo software. Vehicle treated cells are shown in gray; AM extract treated cells are shown in large dashed lines; AM extracts with endotoxin removed are shown in small dashed lines.